Latest market price
103.70
+1.19+1.16%
ABTQT44Abbott Laboratories·NYSE
103.70+1.16%
News
Up 1.2% — Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer (prnewswire.com).
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E38.41EPS (ttm)2.70Insider Own0.61%Shs Outstand1.73BPerf Week-1.13%
Market Cap179.44BForward P/E17.41EPS next Y5.96Insider Trans-3.70%Shs Float1.72BPerf Month2.60%
Enterprise Value206.45BPEG3.50EPS next Q-Inst Own76.44%Short Float0.79%Perf Quarter-0.76%
Income4.70BP/S3.72EPS this Y7.15%Inst Trans0.00%Short Ratio1.41Perf Half Y13.79%
Sales48.23BP/B3.47EPS next Y7.92%ROA4.30%Short Interest13.63MPerf YTD-17.23%
Book/sh29.91P/C32.03EPS next 5Y9.52%ROE9.12%52W High132.03 -21.46%Perf Year-18.95%
Cash/sh3.24P/FCF20.58EPS past 3/5Y-1.65% 8.27%ROIC5.58%52W Low81.97 26.51%Perf 3Y8.52%
Dividend Est.2.52 (2.43%)EV/EBITDA21.26Sales past 3/5Y0.51% 5.08%Gross Margin57.12%Volatility3.96% 2.60%Perf 5Y-11.74%
Dividend TTM2.52 (2.43%)EV/Sales4.28EPS Y/Y TTM-64.66%Oper. Margin15.24%ATR (14)2.87Perf 10Y153.05%
Dividend Ex-DateOct 15, 2026Quick Ratio0.97Sales Y/Y TTM14.97%Profit Margin9.75%RSI (14)53.95Recom2.21
Dividend Gr. 3/5Y7.87% 10.38%Current Ratio1.38EPS Q/Q9.23%SMA202.66%Beta0.54Target Price121.36
Payout90.64%Debt/Eq0.29Sales Q/Q14.46%SMA50-1.40%Rel Volume1.14Prev Close102.51
Employees115,000LT Debt/Eq0.22EarningsJan 28SMA2001.45%Avg Volume9.00MPrice103.70
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.0.03% 0.18%Net Debt/EBITDA2.83Volume10,259,180Change1.16%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-23-26ReiteratedUBSBuy$125 → $120
Oct-23-26ReiteratedWells FargoOverweight$119 → $120
Oct-22-26ReiteratedRobert W. Baird$121 → $123
Oct-22-26ReiteratedWells FargoOverweight$122 → $119
Oct-22-26ReiteratedBTIGBuy$134 → $125
Oct-16-26ReiteratedNew Street$145 → $120
Oct-06-26InitiatedBarclaysOverweight$143 → $120
Oct-02-26ReiteratedRedburn Partners$127
Oct-02-26UpgradeRothschild & CoNeutral → Buy
Aug-13-26UpgradeWolfe ResearchPeer Perform → Outperform$130
Latest News· Times ET
Oct-23-26
Oct-22-26
Oct-21-26
Company

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Ownership
Total institutional ownership76.44%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue48,22944,32841,950——————
Cost of Goods Sold Incl. D&A20,68119,72120,625——————
Gross Profit27,54824,60721,325——————
Selling, General and Administrative Excl. Other14,57312,37811,651——————
Research and Development3,2812,9552,823——————
Other Operating Expense2,3431,2530——————
Operating Income7,3518,0486,825——————
Interest Expense890341603——————
Unusual Expense
—————————
Non-Operating Income (Expense)101759791——————
Net Income Before Taxes6,5628,4667,013——————
Income Taxes1,8611,942-6,389——————
Consolidated Net Income4,7016,52413,402——————
Net Income From Continuing Operations4,7016,52413,402——————
Net Income4,7016,52413,402——————
EPS (Recurring)2.703.747.67——————
EPS (Basic, Before Extraordinaries)2.703.747.67——————
EPS (Diluted)2.703.727.64——————
EBITDA9,71011,92310,834——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio38.4133.6814.80——————
Price To Sales Ratio3.744.944.67——————
Gross Margin57.1255.5150.83——————
Operating Margin15.2418.1616.27——————
Net Margin9.7514.7231.95——————
Shares Outstanding1,7381,7471,732——————
Market Capitalization180,231218,882195,907——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$144.73$127.16$109.59$92.02$74.45● Close Price0.00M11.71M23.42M35.14M46.85MUSD Trades VolumeOctNovDec2026FebMarAprMayJunJulAugSepOct
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLERSep 02 '26Sale109.54272,95824,549Sep 03
Ford Robert BCHAIRMAN AND CEOAug 25 '26Sale115.85398,83246,204,798306,461Aug 27
Ford Robert BCHAIRMAN AND CEOAug 25 '26Option Exercise54.02398,83221,545,946705,293Aug 27
Morrone Louis H.EXECUTIVE VICE PRESIDENTAug 11 '26Sale109.835,850642,50670,724Aug 13
Stratton John GDirectorMay 07 '26Buy86.822,000173,64023,319Jun 18
STARKS DANIEL JDirectorApr 27 '26Buy92.6510,000926,5376,751,103Apr 28
Boudreau Philip PEVP AND CFOApr 23 '26Buy91.502,200201,3002,200Apr 27
Morrone Louis H.EXECUTIVE VICE PRESIDENTMar 02 '26Sale115.581,144132,22476,843Mar 03
Shroff EricSenior Vice PresidentMar 02 '26Sale115.5870981,94639,164Mar 03
Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENTMar 02 '26Sale115.58885102,288146,377Mar 03
Moreland Mary KEXECUTIVE VICE PRESIDENTMar 02 '26Sale115.5861370,851104,291Mar 03
MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLERMar 02 '26Sale115.5858567,61424,628Mar 03
Cushman Elizabeth C.EVP, GC AND SECRETARYMar 02 '26Sale115.5826330,39838,573Mar 03
STARKS DANIEL JDirectorFeb 04 '26Buy108.7310,0001,087,3316,738,817Feb 06
Ford Robert BCHAIRMAN AND CEOJan 23 '26Buy107.1318,8002,013,967216,203Jan 26
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.